Barbara Carpenter
Adult Health · Louisville, KYNPI 1316999774
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,935 of the $7,880 with a category attached, or 75.3%. 25 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 44.3% of the total. Reporting peaked in 2024 at $3,380 and has fallen 56.7% since, to $1,463 in 2025. Among adult health clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 124 payments — averaging $63.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$3K
- AstraZeneca$636
- GSK$407
- Johnson & Johnson$365
- Harmony Biosciences LLC$270
- Idorsia Pharmaceuticals US Inc$262
- plus $2K from 19 others
What the payments were for
- Travel & lodging$1,87324%
- Food & beverage$5,93575%
- Education$721%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 37 | $3,490 |
| AstraZeneca | 8 | $636 |
| GSK | 11 | $407 |
| Johnson & Johnson | 15 | $365 |
| Harmony Biosciences LLC | 3 | $270 |
| Idorsia Pharmaceuticals US Inc | 4 | $262 |
| Axsome Therapeutics, Inc. | 3 | $250 |
| Regeneron Healthcare Solutions, Inc. | 2 | $243 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $197 |
| Angiodynamics, Inc. | 2 | $158 |
| Jazz Pharmaceuticals Inc. | 1 | $148 |
| UCB, Inc. | 4 | $137 |
| Insmed, Inc. | 1 | $137 |
| Boehringer Ingelheim | 4 | $130 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $120 |
| Bayer | 1 | $115 |
| AbbVie | 2 | $114 |
| E.r. Squibb & Sons, L.L.C. | 7 | $109 |
| Exact Sciences | 1 | $105 |
| Shionogi Inc | 5 | $105 |
| Verona Pharma, Inc. | 1 | $103 |
| Lilly USA, LLC | 1 | $95 |
| Novartis | 5 | $90 |
| Sanofi-aventis U.S. LLC | 1 | $60 |
| Merck | 2 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,880 in reported general payments places this provider in the 95th percentile of 170 adult health providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 267 | $237,719 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 93 | $70,562 |
| Spiriva RespimatTiotropium Bromide | 46 | $39,436 |
| Breo ElliptaFluticasone/Vilanterol | 89 | $38,892 |
| SymbicortBudesonide/Formoterol Fumarate | 115 | $34,262 |
| Spiriva HandihalerTiotropium Bromide | 33 | $25,227 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 37 | $21,185 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $14,384 |
| Incruse ElliptaUmeclidinium Bromide | 32 | $12,947 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 81 | $12,204 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 490 | $11,987 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $8,095 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 64 | $7,985 |
| Arnuity ElliptaFluticasone Furoate | 20 | $4,921 |
| BreynaBudesonide/Formoterol Fumarate | 21 | $3,580 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $407 | $308,863437 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $636 | $104,824208 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $130 | $68,717100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 170 adult health providers in Kentucky.
Other adult health in Louisville
- Stephanie FlaspoehlerLouisville$174K
- Heidi GalloLouisville$15K
- Karen EastridgeLouisville$10K
- Loren GarzaLouisville$6K
- Kelly MikeLouisville$4K
- Layla Al-ShamiLouisville$3K
- Brittany McWhorterLouisville$3K
- Lahoma PratherLouisville$2K
- William NapierLouisville$2K
- Barbara LemmonsLouisville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.